<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Seer Inc — News on 6ix</title>
<link>https://6ix.com/company/seer-inc</link>
<description>Latest news and press releases for Seer Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 11:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/seer-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835be8878dffbe2df117af2.webp</url>
<title>Seer Inc</title>
<link>https://6ix.com/company/seer-inc</link>
</image>
<item>
<title>Seer Board of Directors Unanimously Rejects Revised Unsolicited Proposal from Radoff-JEC Group</title>
<link>https://6ix.com/company/seer-inc/news/seer-board-of-directors-unanimously-rejects-revised-unsolicited-proposal-from-radoff-jec-group</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-board-of-directors-unanimously-rejects-revised-unsolicited-proposal-from-radoff-jec-group</guid>
<pubDate>Mon, 27 Apr 2026 11:00:00 GMT</pubDate>
<description>Board Determines Proposal Significantly Undervalues Seer and Is Not in the Best Interests of StockholdersREDWOOD CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors (the “Board”) has thoroughly reviewed and unanimously rejected the revised unsolicited, non-binding proposal received on April 24, 2026 from Bradley L. Radoff and Michael</description>
</item>
<item>
<title>The Radoff-JEC Group Submits Improved Non-Binding Proposal to Acquire Seer, Inc.</title>
<link>https://6ix.com/company/seer-inc/news/the-radoff-jec-group-submits-improved-non-binding-proposal-to-acquire-seer-inc</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/the-radoff-jec-group-submits-improved-non-binding-proposal-to-acquire-seer-inc</guid>
<pubDate>Fri, 24 Apr 2026 11:00:00 GMT</pubDate>
<description>HOUSTON, April 24, 2026--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) ("Seer" or the "Company"), today submitted the following improved non-binding proposal to acquire the Company for $2.35 per share in cash plus a contingent value right.</description>
</item>
<item>
<title>The Radoff-JEC Group Submits Non-Binding Proposal to Acquire Seer, Inc.</title>
<link>https://6ix.com/company/seer-inc/news/the-radoff-jec-group-submits-non-binding-proposal-to-acquire-seer-inc</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/the-radoff-jec-group-submits-non-binding-proposal-to-acquire-seer-inc</guid>
<pubDate>Mon, 13 Apr 2026 12:00:00 GMT</pubDate>
<description>HOUSTON, April 13, 2026--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own approximately 7.6% of the outstanding shares of Seer, Inc. (NASDAQ: SEER) ("Seer" or the "Company"), today submitted the following non-binding proposal to acquire the Company for $2.25 per share in cash plus a contingent value right, and also nominated Howard H. Berman, Joshua S. Horowitz and Luis E. Rinaldini for election to the Board of Director</description>
</item>
<item>
<title>Seer and Precision Health Research, Singapore Sign Collaboration to Provide Deep, Unbiased Proteomics on 10,000 PRECISE SG100K Samples</title>
<link>https://6ix.com/company/seer-inc/news/seer-and-precision-health-research-singapore-sign-collaboration-to-provide-deep-unbiased-proteomics-on-10000-precise-sg100k-samples</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-and-precision-health-research-singapore-sign-collaboration-to-provide-deep-unbiased-proteomics-on-10000-precise-sg100k-samples</guid>
<pubDate>Thu, 09 Apr 2026 12:00:00 GMT</pubDate>
<description>Seer’s Proteograph will be used to generate enhanced proteomic insights in one of the world’s largest multi-omic health studiesREDWOOD CITY, Calif., April 09, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Proteograph® Product Suite, has been selected as the mass spectrometry-based proteomic workflow to deeply profile the plasma proteome in 10,000 participants from PRECISE-SG100K. This unbiased p</description>
</item>
<item>
<title>Patent Board Upholds Seer's Nano and Micro Particle Protein Enrichment Patent in a Challenge by Bruker Subsidiaries</title>
<link>https://6ix.com/company/seer-inc/news/patent-board-upholds-seers-nano-and-micro-particle-protein-enrichment-patent-in-a-challenge-by-bruker-subsidiaries</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/patent-board-upholds-seers-nano-and-micro-particle-protein-enrichment-patent-in-a-challenge-by-bruker-subsidiaries</guid>
<pubDate>Mon, 30 Mar 2026 11:00:00 GMT</pubDate>
<description>23 claims of U.S. Patent No. 11,435,360 remain valid, supporting Seer's Proteograph® Product SuiteREDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leader in deep, unbiased proteomic insights, today announced that the Patent Trial and Appeal Board (“PTAB”) of the U.S. Patent and Trademark Office issued a Final Written Decision on March 23, 2026, in an inter partes review of U.S. Patent No. 11,435,360 B2 (the “’360 Patent”). The inter partes review was filed by</description>
</item>
<item>
<title>Seer Adopts Limited Duration Tax Benefit Preservation Plan to Protect its Valuable Tax Assets</title>
<link>https://6ix.com/company/seer-inc/news/seer-adopts-limited-duration-tax-benefit-preservation-plan-to-protect-its-valuable-tax-assets</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-adopts-limited-duration-tax-benefit-preservation-plan-to-protect-its-valuable-tax-assets</guid>
<pubDate>Thu, 26 Feb 2026 21:06:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that its Board of Directors unanimously adopted a tax benefit preservation plan (“NOL Plan”) designed to help preserve and protect Seer’s valuable income tax net operating loss carryforwards and other tax assets (“NOLs”). As of December 31, 2025, Seer had approximately $262 million of NOLs. These NOLs, most of which are not curr</description>
</item>
<item>
<title>Seer Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Outlook</title>
<link>https://6ix.com/company/seer-inc/news/seer-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-outlook</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-full-year-2026-outlook</guid>
<pubDate>Thu, 26 Feb 2026 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 26, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the fourth quarter and full year ended December 31, 2025. Recent Highlights Generated revenue of $4.2 million for the fourth quarter of 2025 and $16.6 million for the full year 2025Expanded installed base to 82 instruments, representing 67% year-over-year growth, with 33 total instruments installed during th</description>
</item>
<item>
<title>The Radoff-JEC Group Issues Open Letter to Seer Inc.’s Board of Directors Regarding the Immediate Need for Significant Change</title>
<link>https://6ix.com/company/seer-inc/news/the-radoff-jec-group-issues-open-letter-to-seer-incs-board-of-directors-regarding-the-immediate-need-for-significant-change</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/the-radoff-jec-group-issues-open-letter-to-seer-incs-board-of-directors-regarding-the-immediate-need-for-significant-change</guid>
<pubDate>Mon, 23 Feb 2026 13:30:00 GMT</pubDate>
<description>HOUSTON, February 23, 2026--Bradley L. Radoff and Michael Torok (together with certain of their affiliates, the "Radoff-JEC Group"), who collectively own nearly 7.5% of the outstanding common stock of Seer, Inc. (NASDAQ: SEER) ("Seer" or the "Company"), today issued the following open letter to the Company’s Board of Directors.</description>
</item>
<item>
<title>Leading Scientists Demonstrate How Seer’s Proteograph Product Suite Advances Cardiovascular and Neurodegenerative Research at US HUPO 2026</title>
<link>https://6ix.com/company/seer-inc/news/leading-scientists-demonstrate-how-seers-proteograph-product-suite-advances-cardiovascular-and-neurodegenerative-research-at-us-hupo-2026</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/leading-scientists-demonstrate-how-seers-proteograph-product-suite-advances-cardiovascular-and-neurodegenerative-research-at-us-hupo-2026</guid>
<pubDate>Thu, 19 Feb 2026 12:00:00 GMT</pubDate>
<description>Nathan Basisty, Sasha Singh, Bruce Wilcox, and Mozhgan Boroumand among scientific leaders presenting unique proteomics-enabled biological insightsREDWOOD CITY, Calif., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation in the 2026 U.S. Human Proteome Organization (US HUPO) Annual Conference, taking place February 21-25 in St. Louis, Missouri. At the meeting, researchers will demonst</description>
</item>
<item>
<title>Seer to Participate in the TD Cowen 46th Annual Health Care Conference</title>
<link>https://6ix.com/company/seer-inc/news/seer-to-participate-in-the-td-cowen-46th-annual-health-care-conference</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-to-participate-in-the-td-cowen-46th-annual-health-care-conference</guid>
<pubDate>Wed, 18 Feb 2026 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 18, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming TD Cowen 46th Annual Health Care Conference in Boston, MA. Seer’s management is scheduled to participate in a fireside chat on Wednesday, March 4th at 11:10 a.m. Eastern Time / 8:10 a.m. Pacific Time. A live webcast of the session will be available on the Investor section of</description>
</item>
<item>
<title>Seer to Report Fourth Quarter and Full Year 2025 Financial Results on February 26, 2026</title>
<link>https://6ix.com/company/seer-inc/news/seer-report-fourth-quarter-full-210500096</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-report-fourth-quarter-full-210500096</guid>
<pubDate>Thu, 05 Feb 2026 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Feb. 05, 2026 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the fourth quarter and full year 2025 on Thursday, February 26, 2026. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.se</description>
</item>
<item>
<title>Nature Genetics Study Validates Seer’s Proteograph Platform as Essential for Turning Genetic Signals Into Reliable Drug Targets and Biomarkers</title>
<link>https://6ix.com/company/seer-inc/news/nature-genetics-study-validates-seer-120000505</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/nature-genetics-study-validates-seer-120000505</guid>
<pubDate>Mon, 01 Dec 2025 12:00:00 GMT</pubDate>
<description>Large-scale GWAS across ~1,600 samples shows how peptide-level mass spectrometry distinguishes true protein changes from potential binding artifacts resulting from affinity-based approaches, establishing accuracy as the foundation for downstream discoveryREDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced the publication in Nature Genetics of a large genome-wide association study</description>
</item>
<item>
<title>Seer and Collaborators Unveil Broad New Data Demonstrating the Translational Power of Deep Proteomics at HUPO 2025</title>
<link>https://6ix.com/company/seer-inc/news/seer-collaborators-unveil-broad-data-120000664</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-collaborators-unveil-broad-data-120000664</guid>
<pubDate>Fri, 07 Nov 2025 12:00:00 GMT</pubDate>
<description>Studies spanning cardiovascular, aging, and cancer biology highlight how Seer’s Proteograph® platform is enabling discovery at population scaleREDWOOD CITY, Calif., Nov. 07, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced new data to be featured at the Human Proteome Organization (HUPO) World Congress 2025, underscoring how deep, scalable proteomics is transforming the study of human disease. Through a com</description>
</item>
<item>
<title>Seer Reports Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/seer-inc/news/seer-reports-third-quarter-2025-210500651</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-reports-third-quarter-2025-210500651</guid>
<pubDate>Thu, 06 Nov 2025 21:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today reported financial results for the third quarter ended September 30, 2025. Recent Highlights Generated revenue of $4.1 million for the third quarter of 2025Achieved a record quarter for third-party publications and preprints, with more than 60 total to dateEnded the quarter with approximately $251.2 million of cash, cash equivalents and i</description>
</item>
<item>
<title>Seer to Participate in Upcoming November Investor Conferences</title>
<link>https://6ix.com/company/seer-inc/news/seer-participate-upcoming-november-investor-200500518</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-participate-upcoming-november-investor-200500518</guid>
<pubDate>Wed, 29 Oct 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced company management will be participating in the following investor conferences: UBS Global Healthcare Conference in Palm Beach Gardens, FLHosting 1x1 meetings on Wednesday, November 12th Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum in New York, NYFireside chat on Thursday, November 20th at 4:00 p.m.</description>
</item>
<item>
<title>Seer to Report Third Quarter 2025 Financial Results on November 6, 2025</title>
<link>https://6ix.com/company/seer-inc/news/seer-report-third-quarter-2025-200500585</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-report-third-quarter-2025-200500585</guid>
<pubDate>Thu, 16 Oct 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that it will report financial results for the third quarter 2025 on Thursday, November 6, 2025. Company management will be webcasting a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Live audio of the webcast will be available on the Investor section of Seer’s website at investor.seer.bio. An archi</description>
</item>
<item>
<title>RetinalGenix Technologies Contracts with Seer Bio to Explore Early Detection of Neurodegenerative, Systemic, and Retinal Diseases</title>
<link>https://6ix.com/company/seer-inc/news/retinalgenix-technologies-contracts-with-seer-bio-to-explore-early-detection-of-neurodegenerative-systemic-and-retinal-diseases</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/retinalgenix-technologies-contracts-with-seer-bio-to-explore-early-detection-of-neurodegenerative-systemic-and-retinal-diseases</guid>
<pubDate>Thu, 16 Oct 2025 09:01:00 GMT</pubDate>
<description>APOLLO BEACH, Fla., Oct. 16, 2025 (GLOBE NEWSWIRE) -- RetinalGenix Technologies Inc. [OTCQB: RTGN] (“RetinalGenix” or the “Company”), a company developing ultra-high-resolution retinal imaging technology, today announced it has engaged Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, to help identify novel biomarkers that enable earlier detection and more precise monitoring of systemic, neurodegenerative, and retinal diseases. B</description>
</item>
<item>
<title>Seer Highlights How Proteomics Complements Genomics to Advance Precision Medicine at American Society of Human Genetics (ASHG) 2025</title>
<link>https://6ix.com/company/seer-inc/news/seer-highlights-proteomics-complements-genomics-110000101</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-highlights-proteomics-complements-genomics-110000101</guid>
<pubDate>Fri, 10 Oct 2025 11:00:00 GMT</pubDate>
<description>Scientific presentations reveal how Seer’s Proteograph Product Suite is a critical component of multi-omic translational studies and enables profiling of protein isoform-specific biomarkersREDWOOD CITY, Calif., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced its participation at the upcoming American Society of Human Genetics (ASHG) 2025 Annual Meeting, taking place October 14-18 in Boston. As hum</description>
</item>
<item>
<title>Seer Appoints Isaac Ro to its Board of Directors</title>
<link>https://6ix.com/company/seer-inc/news/seer-appoints-isaac-ro-board-110000338</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-appoints-isaac-ro-board-110000338</guid>
<pubDate>Tue, 02 Sep 2025 11:00:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Sept. 02, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced it has appointed Isaac Ro to serve on its Board of Directors. “We are excited to welcome Isaac to our board,” said Omid Farokhzad, Chair and CEO of Seer. “Isaac brings a rare combination of financial leadership and deep sector experience across life science tools, diagnostics, and the broader healthcare ecosystem. His proven tr</description>
</item>
<item>
<title>Seer to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/seer-inc/news/seer-participate-morgan-stanley-23rd-200500303</link>
<guid isPermaLink="true">https://6ix.com/company/seer-inc/news/seer-participate-morgan-stanley-23rd-200500303</guid>
<pubDate>Tue, 26 Aug 2025 20:05:00 GMT</pubDate>
<description>REDWOOD CITY, Calif., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced that the company will be participating in the upcoming Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY. Seer’s management is scheduled to participate in a fireside chat on Tuesday, September 9th at 12:20 p.m. Eastern Time / 9:20 a.m. Pacific Time. A live webcast of the session will be available on the Inv</description>
</item>
</channel>
</rss>